BOSTON — Cardiawave, a pioneering medtech company developing non-invasive ultrasound therapy (NIUT) for aortic stenosis, has appointed Jonathan Freeman, Ph.D., as Chairman of its Board of Directors.
The appointment marks a key milestone in Cardiawave’s growth, reinforcing its ambition to advance new frontiers in the treatment of aortic valve disease. Freeman joins the company at a pivotal time, following the completion of its Valvosoft Pivotal study in Europe and in preparation for its upcoming IDE trial in the United States.
Freeman is a proven leader and entrepreneur with an extensive international track record in building innovative life sciences companies. He co-founded Anthos Therapeutics, a biopharmaceutical firm developing novel therapies for cardiovascular disease, which was acquired by Novartis in May 2025 for up to $3.1 billion. He also serves as a founding board member of Neurvati and GRIN Therapeutics and as Operating Advisor at Blackstone Life Sciences. His earlier career includes senior executive roles at Merck KGaA, Baxter International, Serono, and Vedanta Biosciences.
Freeman holds a Ph.D. in Molecular Pharmacology and an international MBA from Cambridge (MA).
“I joined the Board in July 2025, and based on my observations over the last three months, I am convinced that the company has assembled an outstanding team and will deliver new therapeutic options for millions of patients who have no other choices. The clinical results achieved in Europe are very promising and could transform the treatment of aortic stenosis and more generally, cardiovascular diseases. As Chairman of the Board, I will leverage my entrepreneurial experience and network in the investment community to accelerate Cardiawave’s growth,” said Jonathan Freeman, Ph.D., Chairman of the Board of Directors, Cardiawave.
“We are delighted to welcome Jonathan Freeman as Chairman of our Board. His unique track record as a serial entrepreneur and his ability to raise capital and guide start-ups through growth will be invaluable assets for Cardiawave,” said Carine Schoronoff, CEO of Cardiawave.
